AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and achievement of remission.

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

The company will protect the branded anti-interleukin (IL)-12/23 biologic against sales erosion from pending biosimilars.

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients ...

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...

Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a ...

Gene expression profiling could be a useful method for identifying markers predictive of response to tumor necrosis factor (TNF) blockade in patients with rheumatoid arthritis (RA), according to ...

USA: A recent post hoc analysis of two randomized clinical trials has provided insight into the role of C-reactive protein ...